• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / U.S. Equity

Health Care Mergers Are Just Getting Started

Deals coming fast and furious in the best group in town.
By JIM CRAMER May 21, 2015 | 06:49 PM EDT
Stocks quotes in this article: CVS, OCR, RAD, WBA, MCK, WLP, HUM, AET, CI, UNH, DB, PFE, GSK, MYL, PRGO, VRX, ACT, TEVA, TWTR

We're seeing something amazing in the world of health care: massive consolidation. Shake-and-bake deals coming fast and furious. This morning's acquisition where CVS (CVS) bought Omnicare (OCR) in a $12 billion deal is one more example of what's been going on in this group, and I can tell you that we are in the early innings of these mergers.

Omnicare is a company that provides critical medical care to senior citizens, typically in assisted-living facilities. This is a fabulous niche business that won't be niche as baby boomers get older.

Now, we know CVS already owned a pharmacy benefit manager, Caremark, not that long ago and, when it took tobacco out of its stores, it became CVS Health, much less a drugstore chain and much more a health care provider.

Not that long ago, Rite Aid (RAD) made a similar move to purchase a pharmacy benefit manager, a move I liked very much.

Now I think it is the turn of Walgreens Boots Alliance (WBA) to step up to the plate and buy a company that controls drug costs, or merge with one.  

It's one of the reasons why I think McKesson (MCK) never seems to go down, as it is a formal partner of Walgreens, but I see no reasons why they can't merge. Sure, Walgreens used to own a pharmacy benefit manager and shed it, but that was the old management team and this group isn't bound by history.

Plus, it wouldn't surprise me one bit to see more consolidation in the health maintenance world. Do we really need Anthem (WLP) and Humana (HUM) and Aetna (AET) and Cigna (CI) and United Health (UNH)? I can see a world where five becomes three very easily.

Then there's the rampant talk of mergers in acquisitions among the drug companies. I was amazed yesterday when Deutsche Bank (DB) put out a piece suggesting that Pfizer (PFE) might be soon merging with GlaxoSmithKline (GSK). There was a time when no major firm would even think of having a piece of research that would speculate about such a merger. Now it's a given that a deal has to be done.

Same with the generics. Think of all the combinations there: Mylan (MYL) wants to buy Perrigo (PRGO). Teva (TEVA) wants to buy Mylan. We have come to expect that Valeant (VRX) is always about to pounce on a company in the industry. Even after Actavis (ACT) did the biggest deal of the year in 2014, $70 billion, we keep hearing that CEO Brent Saunders is queueing up another major acquisition.

Why is all this happening? First, there are way too many players bashing each other's heads in the health care segment. Every deal I have seen has raised gross margins dramatically.

Second, many of the users of health care, like the hospitals or doctors, really don't want as many providers calling on them.

Third, the government's gotten stingy, and without the largesse of Medicare, many of these companies can't make their long-term profit margins.

That's why I always reiterate that I like Rite Aid, a company that is asked about on Twitter (TWTR) @jimcramer more than any other. That's why my trust owns Walgreens because any deal it makes will be viewed like the Omnicare deal that CVS did that drove that stock up almost $2.50 today.

It's why I think owning a drug or a biotech is a must.

I understand there are several deals being worked on that could be imminent before the summer begins involving just the players I have reeled off.

My bottom line: Every time there's a deal, the whole group moves. Own one of these; right now it's the single best group in town.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Action Alerts PLUS, which Cramer co-manages as a charitable trust, is long ACT, TWTR and WBA.

TAGS: Investing | U.S. Equity

More from U.S. Equity

Bottom Fishing for Biotech Bargains

Bret Jensen
May 23, 2022 11:45 AM EDT

Here are three names I have added to in May.

A Tide-Turning Rally Is Becoming More Probable

Guy Ortmann
May 23, 2022 9:29 AM EDT

The crowd is essentially entirely on the bear side of the boat.

To Position Yourself for a Potential Rally, Keep an Eye on These Stocks

Bob Byrne
May 23, 2022 8:30 AM EDT

While conditions appear favorable for a bear market bounce, let's not ignore the obvious.

The Week Ahead, Indo-Pacific Deal, S&P 500 Valuation, What I've Been Trading

Stephen Guilfoyle
May 23, 2022 7:33 AM EDT

Markets now have a new reversal to think about, but I think I have to be convinced before I can believe.

Melvin Capital's Demise Presents a Beauty of an Opportunity

Brad Ginesin
May 22, 2022 1:20 PM EDT

The top holder in several companies, the hedge fund's abrupt liquidation has contributed to weakness.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 02:24 PM EDT PAUL PRICE

    An Interesting Chart

    I'm betting heavily that stocks will be way up aga...
  • 10:10 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    "Market Timing for Dummies"
  • 01:44 PM EDT STEPHEN GUILFOYLE

    Stocks Under $10 Portfolio

    We're making a series of trades here.
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login